Evaluation of the Trajectory of Depression Severity With Ketamine and Esketamine Treatment in a Clinical Setting
Sina Nikayin, Taeho Greg Rhee, Maria Elena Cunningham, Christina A. de Fontnouvelle, Robert Ostroff, Gerard Sanacora, Samuel T. Wilkinson
JAMA Psychiatry May 11, 2022 DOI: 10.1001/jamapsychiatry.2022.1074 via OpenAlex
Summary
AI-generated from the abstractIn a clinical setting, patients treated with intravenous ketamine or intranasal esketamine showed similar trajectories of depression severity over time, suggesting both treatments are comparably effective for depression.
Study at a glance
| Characteristics | Comparative analysis Peer reviewed |
|---|---|
| Population | Patients treated with intravenous ketamine or intranasal esketamine in a clinical setting |
| Interventions | Intravenous ketamine Intranasal esketamine |
| Keywords | Otorhinolaryngology Psychiatry Neurology Family medicine Depression economics |
| Citations | 43 |
| Key finding | Patients treated with intravenous ketamine or intranasal esketamine showed similar trajectories of depression severity. |
Abstract
This comparative analysis examines the trajectory of depression severity among patients treated with intravenous ketamine or intranasal esketamine in a clinical setting.